MGTX
HealthcareMeiraGTx Holdings plc · Biotechnology · $860M
What is MeiraGTx Holdings plc?
MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing treatments for serious inherited and degenerative diseases. Its pipeline targets ocular conditions, neurodegenerative disorders, and radiation-induced complications, with several programs already in active clinical trials.
MeiraGTx develops gene therapies designed to address the root genetic causes of disease rather than managing symptoms. The company generates revenue primarily through research collaboration agreements — most notably with Janssen Pharmaceuticals — while advancing its own clinical pipeline. Its proprietary riboswitch technology allows gene expression to be regulated after delivery, a differentiating feature in the gene therapy field. Programs span inherited blindness, dry mouth caused by radiation treatment, and neurodegenerative conditions including Parkinson's disease and ALS.
MeiraGTx was incorporated in 2018 and is headquartered in New York City, US.
- Gene therapies for inherited retinal diseases including Achromatopsia and X-Linked Retinitis Pigmentosa
- Treatment program for radiation-induced Xerostomia in head and neck cancer patients
- Parkinson's disease and ALS neurodegenerative gene therapy programs
- Proprietary riboswitch technology for regulatable gene expression
- Research collaboration with Janssen Pharmaceuticals on gene therapy development
Is MGTX a Good Stock to Buy?
UQS Score rates MGTX as Below Average overall, reflecting the realities of its early-stage clinical profile.
The Growth and Risk pillars stand out as relative strengths within this profile. MeiraGTx carries a pipeline with multiple active clinical programs, and its risk profile — while inherently elevated for a clinical-stage biotech — scores more favorably than many peers at a similar development stage.
The Quality and Moat pillars are both rated Weak, consistent with a pre-revenue company that lacks established commercial products or durable competitive advantages. Valuation is rated Elevated, meaning the market is pricing in significant future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MGTX pay dividends?
No — MeiraGTx Holdings plc does not currently pay a dividend.
MeiraGTx does not pay a dividend, which is typical for clinical-stage biotechnology companies. Available capital is directed toward funding ongoing clinical trials, research collaborations, and pipeline advancement. Investors in MGTX are generally seeking long-term value creation through successful drug development rather than current income.
When does MGTX report earnings?
MeiraGTx reports earnings on a quarterly cadence, consistent with US-listed equities.
As a clinical-stage company, MeiraGTx's quarterly results are driven primarily by collaboration revenue and operating expenses tied to trial activity rather than product sales. Investors typically focus on pipeline milestones and cash runway rather than traditional profitability metrics.
For the most recent quarter's results and upcoming reporting dates, visit MeiraGTx's investor relations page directly.
MGTX Price History
-26.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in MeiraGTx Holdings plc?
Based on MeiraGTx Holdings plc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MGTX Long-term Outlook
MeiraGTx's fundamental outlook is shaped by its Good Growth pillar rating, which reflects the breadth of its clinical pipeline and the potential of gene therapy as a treatment modality. However, the Weak Quality and Moat ratings underscore that commercial validation remains ahead. The Elevated Valuation pillar suggests the current share price already incorporates optimistic assumptions about pipeline success, leaving limited margin for setbacks.
Growth drivers
- Advancement of multiple Phase 1/2 programs toward later-stage clinical milestones
- Expansion of the Janssen collaboration and potential for additional partnership revenue
- Broader adoption of gene therapy as a validated treatment approach in rare diseases
Key risks
- Clinical trial failure or delays across any of the active programs
- Ongoing capital requirements typical of pre-revenue biotech companies
- Elevated valuation leaves little room for pipeline disappointments
MGTX vs Peers
MeiraGTx operates in a competitive clinical-stage biotech landscape alongside other companies developing novel genetic and targeted therapies.
CytomX focuses on Probody therapeutic platforms for oncology, a distinct mechanism from MeiraGTx's gene therapy approach targeting inherited and degenerative diseases.
Compass Therapeutics develops antibody-based cancer treatments, competing for similar clinical-stage investor attention but with a different therapeutic modality than gene therapy.
Design Therapeutics targets genetic diseases using small-molecule approaches, overlapping with MeiraGTx in the rare disease space but differing in its non-viral delivery strategy.
Frequently Asked Questions
What does MeiraGTx do?
MeiraGTx is a clinical-stage gene therapy company developing treatments for inherited and degenerative diseases. Its pipeline includes programs targeting inherited blindness, radiation-induced dry mouth, Parkinson's disease, and ALS. The company also uses a proprietary riboswitch technology that allows gene expression to be regulated after delivery, and has a collaboration with Janssen Pharmaceuticals.
Does MGTX pay dividends?
MGTX does not currently pay a dividend. As a clinical-stage biotech, the company reinvests available capital into its research programs and clinical trials. Dividend payments are not typical for companies at this stage of development, and income-focused investors should factor this into their assessment.
When does MGTX report earnings?
MeiraGTx reports earnings quarterly, in line with standard US-listed company requirements. Because it is pre-commercial, results center on collaboration revenue and trial-related expenses rather than product sales. For exact reporting dates and the most recent results, check MeiraGTx's official investor relations page.
Is MGTX a good stock to buy?
UQS Score rates MGTX as Below Average overall. The Growth and Risk pillars show relative strength, but Quality and Moat are both Weak — reflecting the pre-commercial stage of the business. Valuation is rated Elevated. Whether MGTX fits a portfolio depends on an investor's risk tolerance and time horizon. The full pillar breakdown is available to UQS Pro members.
Is MGTX overvalued?
The UQS Valuation pillar for MGTX is rated Elevated, suggesting the current market price incorporates optimistic assumptions about future pipeline success. For clinical-stage biotechs, valuation is inherently forward-looking and sensitive to trial outcomes. Investors should weigh this against the company's current development stage and cash position.
How does MGTX compare to its competitors?
MeiraGTx competes in the clinical-stage rare disease and genetic therapy space alongside companies like CytomX Therapeutics, Compass Therapeutics, and Design Therapeutics. Each uses a different therapeutic modality — MeiraGTx's gene therapy approach and riboswitch technology distinguish it, though all share the common profile of pre-commercial biotechs with pipeline-dependent valuations.
What is MGTX's market cap bracket?
MGTX is classified as a small-cap stock. This places it in a segment of the market that can offer higher growth potential but also carries greater volatility and liquidity risk compared to large- or mega-cap peers. Small-cap biotechs in particular can experience significant price swings around clinical trial readouts.
Who founded MeiraGTx?
MeiraGTx was incorporated in 2018. Founding and leadership information is publicly available through the company's official filings and investor relations materials for those seeking detailed background on the founding team.
Is MGTX a long-term buy?
As a long-term quality indicator, MGTX's UQS Score is rated Below Average, driven by Weak Quality and Moat scores. The Growth pillar does show promise given the breadth of the pipeline, but long-term quality investing typically favors companies with established competitive advantages and financial durability — areas where MGTX is still developing. Pro members can view the complete analysis.
What is the main competitive advantage of MeiraGTx?
MeiraGTx's most distinctive asset is its proprietary riboswitch technology, which enables gene expression to be turned on or off after delivery — a level of control not common across the gene therapy field. Combined with its multi-program pipeline spanning ocular, salivary, and neurodegenerative diseases, the company has built a differentiated scientific platform, though commercial validation remains ahead.
Is MGTX a growth stock or value stock?
Based on its UQS pillar profile, MGTX leans toward the growth category — the Growth pillar is rated Good, reflecting an active and expanding clinical pipeline. However, the Valuation pillar is rated Elevated, meaning investors are already paying a premium for that potential. It does not exhibit the characteristics typically associated with value investing.
Unlock Full MGTX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access full financial metrics and trend data
- ✓Compare MGTX against sector peers side by side
- ✓See the complete risk and valuation breakdown
- ✓Get alerts when MGTX's score changes materially
Pro Analysis
MGTX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 41.9 | 29.6 | 34.0 | 85.5 | 59.3 | 0.0 | -0.6 |
| Apr 26, 2026 | 42.5 | 29.6 | 34.0 | 87.3 | 61.2 | 0.0 | +4.6 |
| Apr 22, 2026 | 37.9 | 29.6 | 34.0 | 63.9 | 61.2 | 0.0 | +0.3 |
| Apr 2, 2026 | 37.6 | 29.6 | 34.0 | 62.5 | 61.2 | 0.0 | — |
MGTX — Pillar Breakdown
Quality
— 29.6/100 (25%)MeiraGTx Holdings plc currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 85.5/100 (20%)MeiraGTx Holdings plc is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 59.3/100 (15%)MeiraGTx Holdings plc maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)MeiraGTx Holdings plc appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 34/100 (25%)MeiraGTx Holdings plc operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MGTX.
Score Composition
Financial Data
More Stock Analysis
How is the MGTX UQS Score Calculated?
The UQS (Unified Quality Score) for MeiraGTx Holdings plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses MeiraGTx Holdings plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether MeiraGTx Holdings plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.